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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the beneficial and harmful effects of L-ornithine L-aspartate versus placebo, no intervention, or other active interventions for
people with cirrhosis and hepatic encephalopathy.
B A C K G R O U N D
Hepatic encephalopathy is a neuropsychiatric complication asso-
ciated with liver insufficiency or portal-systemic shunting (EASL/
AASLD 2014a; EASL/AASLD 2014b). Hepatic encephalopathy
occurs during the decompensated stage of cirrhosis. The severity
of the impairment ranges from minor signs to overt coma and the
degree of the neuropsychiatric changes increases with the severity
of the underlying liver disease (Bajaj 2009). Previous studies have
found that more than 50% of people with cirrhosis have minimal
hepatic encephalopathy (Lauridsen 2011). Approximately 20%
of people with decompensated cirrhosis have overt hepatic en-
cephalopathy at least once during their clinical course (D’Amico
1986; de Jongh 1992; Zipprich 2012). Both overt and minimal
hepatic encephalopathy are associated with impairment in the per-
formance of complex tasks, such as driving (Schomerus 1981;
Bajaj 2009; Kircheis 2009), and they have a detrimental effect on
quality of life (Groeneweg 1998). The cumulative incidence of
overt hepatic encephalopathy is as high as 40% and is an inde-
pendent predictor of increased mortality (Bustamante 1999; del
Olmo 2000; D’Amico 2006; Spadaro 2007; Stewart 2007; Bajaj
2011). The survival probability in people with cirrhosis after their
first episode of hepatic encephalopathy is about 42% at one year
and 23% at three years (Bustamante 1999).
Description of the condition
Minimal hepatic encephalopathy describes people with cirrhosis
with no clinically apparent signs or symptoms, but with abnor-
malities in neuropsychometric or neurophysiological performance
(Ferenci 2002; Guerit 2009; Atluri 2011). Overt (clinically appar-
ent) hepatic encephalopathy manifests as a neuropsychiatric syn-
drome encompassing a wide spectrum of mental and motor dis-
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orders (Weissenborn 1998; Ferenci 2002). It may develop over a
period of hours or days without an identifiable reason, or be asso-
ciated with precipitating events such as gastrointestinal bleeding,
infection, or alcohol misuse. People may return to normal or may
have some degree of impairment between episodes (Bajaj 2010).
Less frequently, people have stable, persistent neuropsychiatric ab-
normalities often due to extensive spontaneous or surgical portal-
systemic shunting. The changes in mental state range from subtle
alterations in personality, intellectual capacity, and cognitive func-
tion to deep coma. The changes in motor function may include
rigidity, disorders of speech production, tremor, delayed diado-
chocinetic movements, hyper- or hypo-reflexia, choreoathetoid
movements, Babinsky’s sign, and transient focal symptoms (Victor
1965; Weissenborn 1998; Cadranel 2001). Asterixis, also known
asa flapping tremor, is the best known motor abnormality. Indi-
viduals with overt hepatic encephalopathy also show other abnor-
malities such as impaired psychomotor performance (Schomerus
1998), neurophysiological function (Parsons-Smith 1957; Chu
1997), and alterations in cerebral neurochemical/neurotransmitter
homeostasis (Taylor-Robinson 1994), blood flow and metabolism
(O’Carroll 1991), andfluid homeostasis (Haussinger 2000). There
is no gold standard for the diagnosis of this hepatic encephalopa-
thy, but a number of individual techniques exist, which can
be used alone or in combination (Ferenci 2002; Kircheis 2002;
Montagnese 2004; Bajaj 2008; Randolph 2009). Clinicians as
well as researchers generally use the West Haven Criteria to as-
sess changes in the mental state (Conn 1977) and the Glasgow
Coma Score to assess the consciousness level (Teasdale 1974). A
number of paper and pencil psychometric tests are used in the
evaluation of cognitive function. The Psychometric Hepatic En-
cephalopathy Score, which comprises five paper and pencil tests
to assess attention, visual perception, and visuo-constructive abil-
ities, is the most widely used psychometric test (Schomerus 1998;
Weissenborn 2001).
The jointly published guidelines from the European andAmerican
Associations for the Study of Liver diseases (EASL/AASLD 2014a;
EASL/AASLD 2014b) recommend that hepatic encephalopathy
should be classified based on the underlying disease, the severity of
manifestations, the time course, and the existence of precipitating
factors. Hepatic encephalopathy is classed as type A when associ-
ated with acute liver failure, type B when resulting from porto-
systemic bypass or shunting, or type C when associated with cir-
rhosis. The hepatic encephalopathy continuum is subdivided into
episodic, which refers to an acute episode of hepatic encephalopa-
thy (previously known as acute). Recurrent hepatic encephalopa-
thy refers to bouts of hepatic encephalopathy occurringwith a time
interval of six months or less. Persistent hepatic encephalopathy
refers to people with a pattern of behavioral alterations that are
always present and interspersed with relapses of overt hepatic en-
cephalopathy. Previous trials classed recurrent and persistent hep-
atic encephalopathy as chronic, chronic persistent, or chronic in-
termittent hepatic encephalopathy (Stauch 1998). Depending on
the existence of precipitating factors, hepatic encephalopathy is
defined as non-precipitated or precipitated (EASL/AASLD2014a;
EASL/AASLD 2014b).
Description of the intervention
L-ornithine L-aspartate is a stable salt of the amino acids ornithine
and aspartic acid, which is administered orally or intravenously
(Rose 1998; Blanco Vela 2011a). The dose and treatment duration
depends on themode of administration. Previous trials comparing
oral L-ornithine L-aspartate versus lactulose used a dose of nine
grams of L-ornithine-L-aspartate per day (Poo 2006; Poo 2007) or
up to 15 to 18 grams per day (Stauch 1998; Fleig 1999; Rees 2000;
Mittal 2009; Abdo-Francis 2010; Alvares-da-Silva 2011; Mittal
2011; Ndraha 2011; Alvares-da-Silva 2014; Sharma 2014). Trials
assessing intravenous L-ornithine L-aspartate for the treatment of
hepatic encephalopathy in participants with cirrhosis used a total
dose of 20 grams per day for three to eight consecutive days (
Kircheis 1997; Abid 2005; Ahmad2008; Lim2010; Schmid2010;
Abid 2011; Hasan 2012; Sharma 2012; Sharma 2014), but up
to 30 grams per day in participants with transjugular intrahepatic
porto-systemic shunts (Bai 2013a; Bai 2014).
How the intervention might work
Ammonia plays a key role in the pathogenesis of hepatic en-
cephalopathy (Butterworth 2014). Nitrogenous products in the
diet, bacterial metabolism of urea and proteins in the colon, and
deamination of glutamine in the small intestine are the main
sources of ammonia. L-ornithine L-aspartate has ammonia-low-
ering properties, which are affected via stimulation of the urea
cycle in the liver and stimulation of the production of glutamine
in the periphery (Rose 1999). In the liver, ornithine stimulates
the activity of carbamoyl phosphate synthetase while the aspartate
moiety stimulates the activity of arginase through nitrogen dona-
tion. Ammonia is then detoxified into urea (Gebhardt 1997; Rose
1998, Blanco Vela 2011b). L-ornithine L-aspartate also enhances
the activities of ornithine and aspartate transaminases in periph-
eral tissues to promote the production of glutamate, which pre-
dominantly occurs in muscle. The enzyme glutamine synthetase
subsequently converts glutamate to glutamine (Gebhardt 1997).
Why it is important to do this review
Randomised clinical trials (RCTs) in participants with cirrho-
sis have reached different conclusions regarding the effect of
L-ornithine L-aspartate on hepatic encephalopathy for people
with cirrhosis (Kircheis 1997; Stauch 1998; Poo 2006; Ahmad
2008; Schmid 2010; Abid 2011; Mittal 2011; Ndraha 2011;
Alvares-da-Silva 2014; Bai 2014; Sharma 2014). Some trials found
beneficial effects in minimal and overt hepatic encephalopathy
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when used alone (Kircheis 1997; Stauch 1998; Ahmad 2008;
Sharma 2014) or combined with branched-chain amino acids
(Ndraha 2011). Other trials found no convincing effects of L-
ornithine L-aspartate on hepatic encephalopathy (Schmid 2008;
Schmid 2010; Abid 2011; Alvares-da-Silva 2014).
Four meta-analyses have evaluated the effects of L-ornithine L-as-
partate for hepatic encephalopathy (Jiang 2009; Soarez 2009; Perez
Hernandez 2011; Bai 2013b). A meta-analysis published in 2009
included three RCTs with a total of 212 participants (Kircheis
1997; Stauch 1998; Poo 2006) and found that L-ornithine L-as-
partate was associated with a beneficial effect on overt, but not
minimal hepatic encephalopathy compared with placebo or lactu-
lose (Jiang 2009). A meta-analysis of four placebo-controlled trials
with 217 participants (Staedt 1993; Kircheis 1997; Stauch 1998;
Rees 2000) found that although L-ornithine L-aspartate reduced
blood ammonia levels it had no effect on hepatic encephalopa-
thy per se (Soarez 2009). A subsequent meta-analysis from 2011
(PerezHernandez 2011) including five RCTs involving 422 partic-
ipants with cirrhosis (Staedt 1993; Kircheis 1997; Kircheis 2002;
Ahmad 2008; Abdo-Francis 2010) and 1 RCT including 201 par-
ticipants with fulminant liver failure (Acharya 2009) found that L-
ornithine L-aspartate improved neuropsychiatric assessments and
decreased venous blood ammonia concentrations. A meta-anal-
ysis from 2013 (Bai 2013b) evaluated eight trials with 646 par-
ticipants (Kircheis 1997; Stauch 1998; Poo 2006; Ahmad 2008;
Schmid 2010; Abid 2011; Mittal 2011; Ndraha 2011) and found
that L-ornithine L-aspartate was associated with beneficial effects
in overt and minimal hepatic encephalopathy and on fasting am-
monia compared with placebo, no intervention, or lactulose. The
meta-analyses from 2011 and 2013 did not adjust the quantitative
result based on the quality of the evidence and did not include
data from unpublished trials.
We plan to conduct an updated systematic review with meta-anal-
yses of published and unpublished RCTs of L-ornithine L-aspar-
tate for hepatic encephalopathy in people with cirrhosis, follow-
ing recommendations for best practice. Currently, there is no uni-
versally-accepted treatment for hepatic encephalopathy. The ad-
vantage of L-ornithine L-aspartate, should it prove efficacious and
safe, is that it is available not only as an oral preparation but also as
an intravenous infusion; as such it may also be of benefit to people
with acute hepatic encephalopathy which is particularly difficult
to treat.
O B J E C T I V E S
To assess the beneficial and harmful effects of L-ornithine L-aspar-
tate versus placebo, no intervention, or other active interventions
for people with cirrhosis and hepatic encephalopathy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised clinical trials (RCTs) regardless of
their publication status, language, or blinding in our primary anal-
yses. If, during the selection of trials, we identify observational
studies (i.e. quasi-randomised studies; cohort studies; or patient
reports) that report adverse events caused by or associated with
the interventions in our review, we will include these studies for
a review of the adverse events. We will not specifically search for
observational studies for inclusion in this review, which is a known
limitation of our systematic review.
Types of participants
Wewill include participants with cirrhosis who have overt or min-
imal hepatic encephalopathy or who are at risk of developing hep-
atic encephalopathy. We will include participants in our primary
analyses regardless of sex, age, aetiology of the underlying liver
disease or precipitating factors. We will exclude data on people
with acute liver failure.
Types of interventions
We will compare: i) L-ornithine L-aspartate versus placebo or no
intervention; and ii) L-ornithine L-aspartate versus nonabsorbable
disaccharides, antibiotics, probiotics, or branched-chain amino
acids. We will include trials irrespective of the doses, treatment
durations, or mode of administration. We will allow co-interven-
tions administered equally to allocation arms.
We do not plan to include analyses of glycerol phenylbutyrate, or-
nithine phenylacetate, or spherical carbon adsorbents (AST-120),
which will be evaluated in a separate review (Morgan 2016).
Types of outcome measures
We will assess all outcomes at the maximum duration of follow-
up (Gluud 2016).
Primary outcomes
1. Mortality (all-cause).
2. Hepatic encephalopathy. We will assess the outcome using
the primary investigators’ overall assessment of: i) number of
participants who developed hepatic encephalopathy; and ii)
number of participants without a clinically-relevant
improvement in hepatic encephalopathy.
3. Serious adverse events: defined as any untoward medical
occurrence that led to death, was life threatening or required
hospitalisation or prolongation of hospitalisation (ICH-GCP
1997). We will analyse serious adverse events as a composite
outcome (Gluud 2016).
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Secondary outcomes
1. Quality of life.
2. Non-serious adverse events (all adverse events that do no
fulfil the criteria listed under serious adverse events).
3. Liver-related mortality.
Exploratory outcomes
1. Number Connection Test.
2. Portal Hepatic Encephalopathy Score.
3. Blood ammonia concentrations.
4. Electroencephalography.
Search methods for identification of studies
Electronic searches
We will search Cochrane Hepato-Biliary Group Controlled Trials
Register (Gluud 2016), Cochrane Central Register of Controlled
Trials (CENTRAL) in the Cochrane Library, MEDLINE (Ovid
SP), Embase (Ovid SP), and Science Citation Index Expanded
(Web of Science) (Royle 2003). We present preliminary search
strategies with the expected time spans of the searches in Appendix
1.
Searching other resources
We will scan reference lists of relevant articles, and proceedings
from meetings of the British Society for Gastroenterology (BSG),
the British Association for the Study of the Liver (BASL), the Euro-
peanAssociation for the Study of the Liver (EASL), theUnited Eu-
ropeanGastroenterologyWeek (UEGW), theAmericanGastroen-
terological Association (AGA), the American Association for the
Study of Liver Diseases (AASLD), and the International Society
for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).
We will write to the principal authors of trials and the pharma-
ceutical companies involved in the production of L-ornithine L-
aspartate for additional information about completed trials and
for information about any ongoing trials.
We will also search online trial registries such as Clinical-
Trial.gov (clinicaltrials.gov/), EuropeanMedicines Agency (EMA)
(www.ema.europa.eu/ema/), WHO International Clinical Trial
Registry Platform (www.who.int/ictrp), and the Food and Drug
Administration (FDA) (www.fda.gov), as well as pharmaceutical
company sources for ongoing or unpublished trials. We will use
the same or similar search terms as will be used for searching the
electronic databases (Appendix 1).
Data collection and analysis
Selection of studies
Two authors (Caroline Stokes and Ee Teng Goh) will read the
electronic search output, perform additional manual searches, and
list potentially eligible trials. All authors will read the potentially
eligible trials and participate in the final selection of trials for
inclusion. For trials described in more than one publication, we
will select the paper with the longest duration of follow-up as our
primary reference. We will describe the characteristics of included
trials in summary tables, and excluded trials with the reason for
exclusion. A third author (MM or LLG) will act as ombudsman in
case of disagreements. We will resolve contrary opinions through
discussion.
Data extraction and management
The collected data will include information on:
• trials: design (cross-over or parallel), settings (number of
clinical sites; outpatient or inpatient; inclusion period), country
of origin; publication status;
• participants: mean age, proportion of men, aetiology of
cirrhosis, type of hepatic encephalopathy (diagnostic criteria and
definitions/terminology); previous history of hepatic
encephalopathy; and
• interventions: type, dose, duration of therapy, mode of
administration. We will gather the primary and secondary
outcome data, including the definitions used in the assessment of
overall improvement of hepatic encephalopathy, and bias control.
We will request missing data and other information from authors
of included trials.
Assessment of risk of bias in included studies
We will assess bias control using the domains described in the
Cochrane Hepato-Biliary Group module (Gluud 2016), and clas-
sify the risk of bias for separate domains as high, unclear, or low
(Higgins 2011).
Allocation sequence generation
• Low risk of bias: sequence generation achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, or throwing
dice are adequate if performed by an independent person but not
otherwise.
• Unclear risk of bias: not described.
• High risk of bias: the sequence generation method was not
random.
4L-ornithine L-aspartate for people with cirrhosis and hepatic encephalopathy (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation concealment
• Low risk of bias: allocation by a central and independent
randomisation unit, administration of coded, identical drug
containers/vials or sequentially-numbered, opaque, sealed
envelopes.
• Unclear risk of bias: not described.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants and personnel
• Low risk of bias: blinding of participants and personnel
using placebo, double dummy or similar. We will define lack of
blinding as not likely to affect the assessment of mortality.
• Unclear risk of bias: not described.
• High risk of bias: no blinding or incomplete blinding, and
the assessment of outcomes were likely to be influenced by lack
of blinding (non-mortality outcomes).
Blinding of outcome assessors
• Low risk of bias: blinding of the outcome assessor using a
placebo, double dummy or similar. We will define lack of
blinding as not likely to affect the assessment of mortality.
• Unclear risk of bias: there was insufficient information.
• High risk of bias: no blinding or incomplete blinding, and
the assessment of outcomes were likely to be influenced by lack
of blinding (non-mortality outcomes).
Incomplete outcome data
• Low risk of bias: missing data unlikely to make treatment
effects depart from plausible values. The investigators used
sufficient methods, such as intention-to-treat analyses with
multiple imputations or carry-forward analyses, to handle
missing data.
• Unclear risk of bias: insufficient information.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported clinically-relevant
outcomes (mortality, hepatic encephalopathy, and serious adverse
events). If we had access to the original trial protocol, the
outcomes selected were those called for in that protocol. If we
obtained information from a trial registry (such as
www.clinicaltrials.gov), we only used that information if the
investigators registered the trial before inclusion of the first
participant.
• Unclear risk of bias: not all predefined outcomes were
reported fully, or it was unclear whether data on these outcomes
were recorded or not.
• High risk of bias: one or more predefined outcomes were
not reported.
For-profit bias
• Low risk of bias: the trial appears to be free of industry
sponsorship or other type of for-profit support.
• Unclear risk of bias: insufficient information about support
or sponsorship.
• High risk of bias: the trial received funding or other support
from a pharmaceutical company.
Other bias
• Low risk of bias: the trial appeared to be free of other biases
including: medicinal dosing problems or follow-up (as defined
below).
• Unclear risk of bias: the trial may or may not have been free
of other factors that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias such as the administration of
inappropriate treatments being given to the controls (e.g. an
inappropriate dose) or follow-up (e.g. the trial included different
follow-up schedules for participants in the allocation groups).
Overall bias assessment
• Low risk of bias: all domains were low risk of bias using the
definitions described above.
• High risk of bias: one or more of the bias domains were of
unclear or high risk of bias.
Measures of treatment effect
We will use risk ratios (RR) for dichotomous outcomes and the
standardised mean differences (SMD) for continuous outcomes,
both with 95% confidence intervals (CI). For our primary out-
comes, we will calculate the number needed to treat for an ad-
ditional beneficial outcome (NNTB) based on the risk difference
(RD) as 1/RD (Higgins 2011).
Unit of analysis issues
We will include data from the first treatment period of cross-over
trials. We will include separate pair-wise comparisons from multi-
arm trials. Accordingly, if a trial compares L-ornithine L-aspartate,
rifaximin, and lactulose, we will conduct separate analyses of L-
ornithine L-aspartate versus rifaximin and L-ornithine L-aspartate
versus lactulose.
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Dealing with missing data
We will extract data on all randomised participants in order to al-
low intention-to-treat analyses and conduct a worst-case scenario
analysis using simple imputation (Higgins 2008). Our worst-case
scenario analysis will include participants with missing outcome
data in the intervention arm and those in the control arm as suc-
cesses. We will also conduct an extreme worst-case scenario anal-
ysis in which missing outcome data are counted as failures in the
experimental arm and successes in the control arm (Gluud 2016).
Assessment of heterogeneity
We will express heterogeneity as I2 values using the following
thresholds: 0% to 40% (unimportant), 40% to 60% (moderate),
60% to 80% (substantial), and > 80% (considerable), and include
information in the ’Summary of findings‘ tables.
Assessment of reporting biases
For meta-analyses with at least 10 RCTs, we will assess reporting
biases through regression analyses and funnel plots.
Data synthesis
We will perform the analyses in Review Manager 5 (RevMan
2014), STATA (Stata version 14), and Trial Sequential Analysis
(TSA 2011).
Meta-analysis
In our primary analyses, we will stratify trials based on the type
of control intervention (e.g. placebo or no intervention, nonab-
sorbable disaccharides, antibiotics, probiotics, andbranched-chain
amino acids). We plan to compare the fixed-effect and random-
effects estimates of the intervention effect. If the estimates are sim-
ilar, then we will assume that any small-study effects have little
effect on the intervention effect estimate. If the random-effects
estimate is more beneficial, we will re-evaluate whether it is rea-
sonable to conclude that the intervention was more effective in
the smaller studies. If the larger studies tend to be those conducted
with greatermethodological rigour, or conducted in circumstances
more typical of the use of the intervention in practice, thenwe will
report the results of meta-analyses restricted to the larger, more
rigorous studies. Based on the expected clinical heterogeneity, we
expect that a number of analyses will display statistical between-
trial heterogeneity (I2 > 0%). For random-effects models, preci-
sion will decrease with increasing heterogeneity and confidence
intervals will widen correspondingly. We therefore expect that the
random-effects model will give the most conservative (and a more
correct) estimate of the intervention effect. Accordingly, we plan
to report the results of our analyses based on random-effects meta-
analyses.
Trial Sequential Analysis
We will perform Trial Sequential Analysis (Wetterslev 2008; TSA
2011) to evaluate the risk of type 1 and type 2 errors and to evaluate
futility (Higgins 2008) in the analyses of our primary outcomes.
We will define the required information size (also known as the
’heterogeneity adjusted required information size’) as the number
of participants needed to detect or reject an intervention effect
based on the relative risk reduction (RRR) and assumed control
risk (ACR). We will define firm evidence as established if the Z-
curve crosses the monitoring boundary (also known as the ’trial
sequential monitoring boundary’) before reaching the required in-
formation size. We will construct futility boundaries to evaluate
the uncertainty of obtaining a chance neutral finding. We will per-
form the analyses with alpha set to 5%, power to 80%, andmodel-
based diversity. We will conduct the analyses including all RCTs
and including RCTs with a low risk of bias. Based on previous
evidence (Kircheis 1997; Stauch 1998; Fleig 1999; Ahmad 2008;
Mittal 2009; Schmid 2010; Abid 2011;Mittal 2011; Hasan 2012;
Sharma 2014), we will set the RRR to 20% and the ACR to 15%
in the analysis of mortality, the RRR to 30% and the ACR to 45%
in the analysis of hepatic encephalopathy, and the RRR to 25%
and ACR to 20% in the analysis of serious adverse events.
Subgroup analysis and investigation of heterogeneity
We will undertake subgroup analyses to investigate heterogeneity
based on stratificationof trials by risk of bias and the type of hepatic
encephalopathy (overt, minimal, or prevention; acute or chronic
(corresponding to episodic or recurrent); andprimary or secondary
prevention). We will also compare RCTs evaluating intravenous
or oral L-ornithine L-aspartate.
Sensitivity analysis
We plan to perform sensitivity analyses excluding RCTs that in-
clude participants with iatrogenic shunts, and to conduct worst-
case and extreme worst-case scenario analyses (as described above).
’Summary of findings’ tables
We will use the GRADE system (Brozek 2008) to evaluate the
quality of the evidence for outcomes reported in the review, con-
sidering the within-trial risk of bias, inconsistency, imprecision,
indirectness, and publication bias. We will include the informa-
tion in the interpretation of our results and report conclusions
based on the ’EPICOT’ principle (Brown 2006).
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Database Time span Search strategy
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
Date will be given at review stage. (ornit* and aspart*) and hepatic encephalopath*
Cochrane Central Register of Controlled
Trials
(CENTRAL) in the Cochrane Library
Latest issue #1 ornit* in All Text
#2 MeSH descriptor Ornithine explode all trees
#3 aspart* in All Text
#4MeSH descriptor Aspartic Acid explode all trees
#5 (#1 or #2) and (#3 or #4)
#6 cirrhosis in All Text
#7 Encephalopath* in All Text
#8 MeSH descriptor Hepatic Encephalopathy ex-
plode all
trees
#9 #6 or #7 or #8
#10 #5 and #9
MEDLINE (Ovid SP) 1946 to the date of search. #1 Randomized controlled trial pt.
#2 Controlled clinical trial.pt.
#3 exp Randomized controlled trial/
#4 exp Random allocation/
#5 exp Double-blind method/
#6 exp Single-blind method/
#7 clinical trial.pt.
#8 exp clinical trial/
#9 (clin$ adj25 trial$).ti,ab.
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
or #9
#11 singl$ or doubl$ or tripl$ or trebl$).ti,ab.
#12 (blind$ or mask$).ti,ab.
#13 #11 and #12
#14 exp Placebos/
#15 placebo$.ti,ab.
#16 random$.ti,ab.
#17 #14 or #15 or #16
#18 #10 or #13 or #17
#19 animals/ not humans/
#20 #18 not #19
#21 exp Ornithine/
#22 exp Aspartic Acid/
#23 #21 and #22
#24 (ornit$ and aspart$).ti,ab.
#25 #23 or #24
#26 exp Hepatic Encephalopathy/
#27 Encephalopathy.ti,ab.
#28 cirrhosis.ti,ab.
#29 #26 or #27 or #28
#30 #20 and #25 and #29
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(Continued)
Embase (Ovid SP) 1974 to the date of search. #1 Controlled study/
#2 Randomized Controlled trial/
#3 double blind procedure/
#4 single blind procedure/
#5 crossover procedure/
#6 drug comparison/
#7 placebo/
#8 random*.ti, ab.
#9 crossover.ti,ab.
#10 cross-over.ti, ab.
#11placebo*.ti,ab.
#12 ((doubl* or singl* or tripl* or trebl*) AND
(blind* or
mask*)).ti, ab.
#13 (comparative AND trial*).ti,ab.
#14 (clinical AND trial*).ti,ab.
#15 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
or #9 or
#10 or #11 or #12 or #13 or #14
#16 nonhuman/
#17 animal/ not (human/ and animal/)
#18 #16 or #17
#19 #15 not #18
#20 ’aspartic acid’/
#21 ’ornithine’/
#22 #20 and #21
#23 ornit*.ti, ab.
#24 aspart*.ti, ab.
#25 #23 and #24
#26 #22 or #25
#27 ’hepatic encephalopathy’/
#28 encephalopath*.ti, ab.
#29 #27 or #28
#30 #19 and #26 and #29
Science Citation Index Expanded (Web of
Science)
1900 to the date of search. #1 TS=(ornit* and aspart*)
#2 TS=(hepatic encephalopath*)
#3 #1 and #2
#4 TS=(random* OR blind* OR placebo* OR
meta-analys*
OR systematic review*)
#5 #3 and #4
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N O T E S
This protocol replaces a previous protocol by Yuan W et al., with the title ’L-ornithine-L-aspartate for hepatic encephalopathy’, that
was abandoned in 2011 (Yuan 2008) and withdrawn from publication.
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